If possible during the current COVID-19 pandemic, patients requiring anticoagulant therapy for deep vein thrombosis, venous stent therapy, and nonvalvular atrial fibrillation should be converted to NOACs for decreasing their need to travel from home to avoid COVID-19 transmission without increasing their risk for anticoagulant therapy-related complications.